Search results

* '''Mucomyst''' ([[Bristol-Myers Squibb]])

...tablets, topical [[ointment]], and [[pessary|pessaries]], [[Bristol-Myers Squibb]]) *Mycostatin (vaginal tablets, topical powder, [[Bristol-Myers Squibb]])

...of Health]] (NIH) awarded a ten-year exclusive licensed to [[Bristol-Myers Squibb]] Co. (BMS) to market and sell ddI as Videx tablets. [[Category:Bristol-Myers Squibb]]

...itabine, tenofovir and [[efavirenz]] (Sustiva, marketed by [[Bristol-Myers Squibb]]) was approved by the [[Food and Drug Administration (United States)|U.S.

[[Category:Bristol-Myers Squibb]]

[[Category:Bristol-Myers Squibb]]

...dy available in the anti-HIV combination [[Truvada]]) with [[Bristol-Myers Squibb]]'s [[efavirenz]] into a fixed-dose pill. Combining the three drugs into a ...pe, Atripla is marketed jointly by [[Gilead Sciences]] and [[Bristol-Myers Squibb]], but in much of the developing world, marketing and distribution is handl

...vedate=29 September 2007}}</ref> Produced under license by [[Bristol-Myers Squibb]], Glucophage was the first branded formulation of metformin to be marketed ...s, and is absorbed slowly.<ref name=PI>{{vcite web |author=[[Bristol-Myers Squibb]] |url=http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020357s031,

...rketed outside [[Japan]] by the [[pharmaceutical company]] [[Bristol-Myers Squibb]]. [[Category:Bristol-Myers Squibb]]

| Germany, Norway, Spain ([[Bristol-Myers Squibb]])

[[Category:Bristol-Myers Squibb]]